Bigul

Aarti Drugs Ltd - 524348 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAARTI DRUGS LTD. 2CININE767A01016 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 450 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Rushikesh Deole Designation: Company Secretary & Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Adhish Patil Designation: Chief Financial Officer EmailId: [email protected] Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996

Please find enclose herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2019 received from Link Intime India Pvt. Ltd., Registrar and Share Transfer Agent of our Company
30-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Letter of Offer

Inga Advisors Private Limited ("Manager to the Buyback Offer") has submitted to BSE a copy of Letter of Offer to the Equity Shareholders of Aarti Drugs Ltd ("the Company").
30-04-2019
Bigul

Aarti Drugs Ltd - 524348 - Compliance Certificate For The Half Year Ended March 31, 2019

Compliance Certificate pursuant to Regulation 7(3) of the SEBI (LODR) Regulations, 2015.
27-04-2019
Bigul

Aarti Drugs Ltd - 524348 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject, please find attached herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 received from Jagdish Patel & Co., Practicing Company Secretary, for the period from October 1, 2018 to March 31, 2019.
26-04-2019
Bigul

Aarti Drugs Ltd - 524348 - Appointment Of Company Secretary And Compliance Officer

This is to inform you that Mr. Rushikesh Deole (ICSI M.No. A54527) has been appointed as the Company Secretary and Compliance Officer of the Company w.e.f. April 23, 2019.
24-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Statement Of Investor Complaints For The Quarter Ended March 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0752 Name of the Signatory :- Adhish P. PatilDesignation :- Authorised Signatory
20-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
20-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Shareholding for the Period Ended March 31, 2019

Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here
20-04-2019
Bigul

AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
09-04-2019
Next Page
Close

Let's Open Free Demat Account